<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doses of antimicrobials used for &lt;em&gt;Mycobacterium abscessus&lt;/em&gt; pulmonary disease in adults&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doses of antimicrobials used for <em>Mycobacterium abscessus</em> pulmonary disease in adults<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Doses of antimicrobials used for <em>Mycobacterium abscessus</em> pulmonary disease in adults<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Intravenous agents</td> </tr> <tr> <td class="indent1">Amikacin</td> <td> Initial: <ul class="decimal_heading"> <li>10 to 15 mg/kg intravenously once daily*</li> </ul> <ul class="decimal_heading none"> <li><strong>or</strong></li> </ul> <ul class="decimal_heading"> <li>15 to 25 mg/kg three times per week</li> </ul> </td> <td>Subsequently adjust the dose to provide peak serum levels above the amikacin MIC (preferably at least 2 to 3 times the MIC) while avoiding peak levels &gt;35 mcg/mL.*</td> </tr> <tr> <td class="indent1">Imipenem</td> <td>0.5 to 1 g intravenously two or three times daily<sup>¶</sup></td> <td>We prefer twice-daily dosing.</td> </tr> <tr> <td class="indent1">Cefoxitin</td> <td>6 to 8 g intravenously per day in divided doses<sup>¶</sup></td> <td>We typically use 4 g twice daily.</td> </tr> <tr> <td class="indent1">Tigecycline</td> <td>25 mg to 50 mg intravenously once to twice daily</td> <td> <p>Dosing is often limited by nausea and vomiting.</p> We typically use a maximum daily dose of 50 mg. Patients generally cannot tolerate 50 mg twice daily for a prolonged period.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Oral agents</td> </tr> <tr> <td class="indent1">Azithromycin</td> <td>250 to 500 mg orally once daily or 500 mg three times per week</td> <td> </td> </tr> <tr> <td class="indent1">Clarithromycin</td> <td>500 mg twice daily administered orally every day or 3 times per week</td> <td> </td> </tr> <tr> <td class="indent1">Clofazimine</td> <td>100 mg orally once daily</td> <td>In the United States, clofazimine is not commercially available but can be requested by filing a single-patient investigational new drug application with the FDA.</td> </tr> <tr> <td class="indent1">Omadacycline</td> <td>300 mg orally once daily</td> <td>This can also be administered intravenously (100 mg once daily).</td> </tr> <tr> <td class="indent1">Tedizolid</td> <td>200 mg orally once daily</td> <td> </td> </tr> <tr> <td class="indent1">Linezolid</td> <td>600 mg orally once daily</td> <td>For those who cannot tolerate 600 mg daily, we often suggest they cut the tablet in half and take 300 mg orally once daily.</td> </tr> <tr> <td class="indent1">Bedaquiline</td> <td> <p>400 mg orally once daily for 2 weeks</p> <p class="indent1"><strong>then</strong></p> 200 mg orally three times per week</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Inhaled agent</td> </tr> <tr> <td class="indent1">Amikacin</td> <td> <p>Parenteral formulation: 250 to 500 mg inhaled once daily</p> Amikacin liposome inhalation suspension: 590 mg inhaled once daily</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Evidence to inform optimal antimicrobial dosing for <em>M. abscessus</em> lung disease is limited. The recommendations presented in this table reflect the author's approach and take into consideration the potential for toxicity over a prolonged treatment course. Patients should be managed in consultation with a specialist who has experience treating <em>M. abscessus</em> disease. Dosing in this table is intended for adult patients with normal organ (ie, kidney, liver) function. For dose adjustments, refer to Lexicomp drug monographs included with UpToDate.</div><div class="graphic_footnotes"><p>MIC: minimum inhibitory concentration; FDA: US Food and Drug Administration.</p>
<p>* The optimal dosing and peak levels of amikacin for <em>M. abscessus</em> infection are not established and remain controversial; in particular, the maximum peak levels for three times weekly dosing is uncertain. At 25 mg/kg per dose, peak levels would likely exceed 35 mcg/mL. Nevertheless, the author's practice is to maintain peak levels ≤35 mcg/mL regardless of dosing interval. For any dosing approach, careful monitoring for amikacin toxicity (especially ototoxicity) is critical.</p>
¶ We typically use twice-daily dosing. Dosing of intravenous medications three times a day is generally impractical for most patients, particularly those who receive their medications at an infusion center.</div><div class="graphic_reference">References:
<ol>
<li>Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</li>
<li>Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest 2022; 161:64.</li>
</ol></div><div id="graphicVersion">Graphic 140263 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
